Anaconda内移植物在EVAR术后肢体闭塞的发生率与治疗
单中心回顾性研究纳入317例腹主动脉瘤EVAR患者,比较第二代与第三代Anaconda支架肢体闭塞率。第二代1、2、5年通畅率分别为96.6%、89.9%、86.5%,第三代分别为95.0%、95.0%、88.6%。多因素分析显示小远端移植物直径是肢体闭塞唯一独立预测因子(HR 0.732, 95%CI 0.63-0.86, p<0.001)。
要点
- 第二代与第三代Anaconda支架总体肢体闭塞率无显著差异。
- 择期患者第三代支架闭塞率6.4% vs 13.1%,临床相关但未达统计学显著。
- 远端移植物直径≤13 mm时闭塞率增加。
核心结论
- Anaconda支架在符合IFU的日常实践中能有效隔绝AAA,但肢体闭塞率仍可进一步降低。
研究设计与样本
- 单中心回顾性研究纳入317例连续EVAR患者,平均年龄76岁,289例男性。
- 2003年9月至2011年7月使用第二代支架189例(平均77岁,169例男性)。
- 2011年7月至2015年9月使用第三代支架128例(平均75岁,120例男性)。
- 比较两组肢体闭塞率及IFU依从性,多因素分析寻找预测因子。
主要发现
- 第二代与第三代支架1年免于闭塞率分别为96.6%和95.0%。
- 第二代与第三代支架2年免于闭塞率分别为89.9%和95.0%。
- 第二代与第三代支架5年免于闭塞率分别为86.5%和88.6%。
- 第二代支架总体闭塞率无显著差异(p=0.332),IFU内使用亦无差异(p=0.827)。
- 择期患者第三代支架闭塞率6.4% vs 13.1%(p=0.077)。
关键数值与推荐
- 远端移植物直径≤13 mm时肢体闭塞率增加。
- 第二代支架1、2、5年免于闭塞率:96.6%、89.9%、86.5%。
- 第三代支架1、2、5年免于闭塞率:95.0%、95.0%、88.6%。
- 择期患者第三代支架闭塞率6.4%,第二代13.1%。
临床怎么用
- 选用Anaconda支架时应关注远端移植物直径,避免≤13 mm以降低肢体闭塞风险。
- 症状性或破裂AAA患者EVAR术后需警惕肢体闭塞风险增高。
- 第三代Anaconda支架在择期患者中可能降低肢体闭塞率。
局限性
- 单中心回顾性研究,样本量有限。
- 择期患者闭塞率差异未达统计学显著(p=0.077)。
- 症状性/破裂AAA风险增加未达统计学显著(p=0.078)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the incidence and treatment of limb occlusions of the second- and third-generation Anaconda endografts. METHODS: A single-center retrospective study was conducted involving 317 consecutive patients (mean age 76 years; 289 men) who underwent endovascular aneurysm repair for elective asymptomatic, symptomatic intact, and ruptured infrarenal abdominal aortic aneurysm with 2 versions of the Anaconda device. From September 2003 to July 2011, the second-generation device was used in 189 patients (mean age 77 years; 169 men) and from July 2011 to September 2015, the third-generation device was implanted in 128 patients (mean age 75 years; 120 men). The rates of limb occlusion were compared between groups and according to compliance with the instructions for use (IFU); predictors were sought in multivariate analysis. The results of the latter are given as the hazard ratio (HR) and 95% confidence interval (CI). RESULTS: Kaplan-Meier freedom of occlusion estimates for second- and third-generation devices, respectively, was 96.6% and 95.0% at 1 year, 89.9% and 95.0% at 2 years, and 86.5% and 88.6% at 5 years. There was no significant difference in overall occlusion rate between the second-generation devices (p=0.332) or with regard to use within the IFU (p=0.827); however, there was a clinically relevant decrease in the occlusion rate for elective patients treated with the third-generation device (6.4% vs 13.1%, p=0.077). There was an increase in the occlusion rate when the iliac limb diameter was ≤13 mm. In multivariate analysis, the only independent predictor of limb occlusion was a small distal prosthesis diameter (HR 0.732, 95% CI 0.63 to 0.86, p<0.001). Symptomatic nonruptured and ruptured abdominal aortic aneurysm (AAA) interventions had an almost 2-fold increased risk of occlusion (HR 1.95, 95% CI 0.93 to 4.11, p=0.078), though this did not reach statistical significance. CONCLUSION: The Anaconda design has proven effectiveness in AAA exclusion in daily practice inside the IFU. However, efforts could be made to further reduce the limb occlusion rate.
引用
- Rödel SGJ, Zeebregts CJ, Meerwaldt R, et al. Incidence and Treatment of Limb Occlusion of the Anaconda Endograft After Endovascular Aneurysm Repair. J Endovasc Ther. 2018. PMID: 30760133. doi:10.1177/1526602818821193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。